Skip to main content
Premium Trial:

Request an Annual Quote

Karius Secures $25M Loan

NEW YORK (GenomeWeb) — Karius announced today that it has reached a deal for a $25 million senior secured term loan from financing firm Oxford Finance.

Specific terms of the loan were not disclosed.

Redwood City, California-based Karius said it intends to use the money to continue commercialization of its diagnostic technologies, to fund clinical studies, and for research and development activities.

"Oxford Finance realizes Karius' potential to transform the diagnostic landscape for infectious diseases," Karius CEO Mickey Kertesz said in a statement. "This capital will enable Karius to help more patients by expanding its reach."

Karius recently launched a next-generation sequencing-based test capable of detecting over 1,000 pathogens — including bacteria, DNA viruses, fungi, mold, and protozoa — from microbial cell-free DNA in a single blood draw. Last month, the Stanford University spinout signed on São Paulo-based medical diagnostics firm Dasa to distribute the test in Brazil, and collaborators presented interim study results and anecdotal evidence on the assay.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.